What is the P/E ratio of Twilight Litaka Pharma?

The latest standalone P/E ratio of Twilight Litaka Pharma as of 01-Jan-1970 is 0.00.

What is the P/B ratio of Twilight Litaka Pharma?

The latest standalone P/B ratio of Twilight Litaka Pharma as of 01-Jan-1970 is -0.05.

Twilight Litaka Pharma Ltd - Stock Valuation and Financial Performance

Name: Twilight Litaka Pharma
Brand: Twilight Litaka Pharma

BSE: 506985 | NSE: TWILITAKA | Pharmaceuticals & Drugs | Small Cap

Place order

BSE Share Price
Not Listed

DeciZen - make an informed investing decision on Twilight Litaka Phar

Based on:

Data

M-Cap below 100cr DeciZen not available

Twilight Litaka Pharma stock performance -

PE Chart Key Ratios

Price Chart, Live Stock Chart, Technical Chart of

P/E Ratio (SA):

0.00

Market Cap:

7.1 Cr.

52-wk low:

2.9

52-wk high:

2.9

Related Stocks

Is an attractive stock to invest in?

1. Is a good quality company?

Data is not available for this company.

2. Is undervalued or overvalued?

No data found

3. Is a good buy now?

No data found

10 Year X-Ray of Twilight Litaka Phar:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Jun'13	Jun'14	TTM
ROCE % ⓘ	15.5%	30.7%	30%	29.4%	25.3%	25.7%	28%	11.2%	-40.5%	-55.6%	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	69.5	154	198	295	370	492	657	730	270	31.5	12
Sales YoY Gr.	-	122.3%	27.9%	49.3%	25.6%	32.8%	33.6%	11.1%	-63%	-88.3%	-
Adj EPS ⓘ	-0.6	9.3	6.6	8.5	9.8	14.9	22.5	1.2	-52.6	-56.3	-59.4
YoY Gr.	-	NA	-29.5%	29.9%	15.3%	51.7%	51.3%	-94.7%	-4517.7%	NA	-
BVPS (₹) ⓘ	-1.4	8.8	13.6	20.9	30.1	43.6	64.7	71	4.2	-51	-58
Adj Net Profit ⓘ	-0.5	8.9	14	18.1	20.9	31.7	48	3	-130	-140	-147
Cash Flow from Ops. ⓘ	3.7	-7.3	-2.4	-18.7	5.2	14.2	-5.5	1.5	-4.6	1.7	-
Debt/CF from Ops. ⓘ	8.4	-8	-28.2	-6.4	31.1	13.8	-47.2	199.2	-53.1	182.5	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-8.4%	-38.9%	-63.7%	-88.3%
Adj EPS ⓘ	NA	-241.8%	-235.7%	NA
BVPSⓘ	NA	-211.2%	-192.4%	-1303.5%
Share Price	-	-	-	-

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Jun'13	Jun'14	TTM
Return on Equity % ⓘ	-15.5	59	46.2	42.7	34.9	36.1	37.4	1.8	-162.8	273.1	109
Op. Profit Mgn % ⓘ	4.1	10	13.5	13	13.2	13.6	14.9	9.4	-12.2	-27.8	15.3
Net Profit Mgn % ⓘ	-0.8	5.8	7.1	6.2	5.6	6.4	7.3	0.4	-48.3	-443.1	-1178.7
Debt to Equity ⓘ	-22.7	6.9	2.3	2.7	2.5	2.1	1.9	1.7	23.4	-2.4	-
Working Cap Days ⓘ	133	115	159	168	193	183	180	203	422	3,261	2,538
Cash Conv. Cycle ⓘ	48	67	109	123	148	146	142	164	353	2,725	-2,350

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Twilight Litaka Pharma Ltd.

	Standalone	Consolidated
TTM EPS (₹)	-59.4	-56.6
TTM Sales (₹ Cr.)	12.5	31.5
BVPS (₹.) ⓘ	-58	-55.7
Reserves (₹ Cr.) ⓘ	-156	-150
P/BV ⓘ	-0.05	-0.05
PE ⓘ	0.00	0.00

From the Market
52 Week Low / High (₹)	2.88 / 2.88
All Time Low / High (₹)	0.68 / 203.90
Market Cap (₹ Cr.)	7.1
Equity (₹ Cr.)	12.4
Face Value (₹)	5
Industry PE ⓘ	37.5

Quarterly Results

Standalone Basis

Consolidated Basis

	Jun'14	YoY Gr. Rt. %	Sep'14	YoY Gr. Rt. %	Dec'14	YoY Gr. Rt. %	Mar'15	YoY Gr. Rt. %
Sales (₹ Cr.)ⓘ	3.2	-71.3	2.3	-77.1	4.4	-53	2.7	-70.6
Adj EPS (₹) ⓘ	-15.4	N/A	-0.3	N/A	-1.4	N/A	-1.6	N/A
Op. Profit Mgn % ⓘ	23.26	38696 bps	19.69	15360 bps	51.95	6342 bps	-57.94	-5350 bps
Net Profit Mgn % ⓘ	-1202.02	-88674 bps	-32.94	11354 bps	-77.69	-5313 bps	-144.35	-12724 bps

Management X-Ray of Twilight Litaka Phar:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

98.08

91.37

72.58

4.85

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Twilight Litaka Phar

Analyst's Notes

No data found!

Key Ratios of Twilight Litaka Phar

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Price Chart, Live Stock Chart, Technical Chart of

Sales (Cr.)

Price Chart, Live Stock Chart, Technical Chart of

ROE (%)

Price Chart, Live Stock Chart, Technical Chart of

ROCE (%)

Company Name	CMP(₹)	Change ₹(%)	Market Cap	Net Sales (₹ Cr.)	Latest EPS (₹)	Net Profit Margin %	Latest P/E	Latest P/BV
Alembic Pharma	828	22.5 (2.8%)	Small Cap	6,229	30.8	9.6	26.2	3.2
Laurus Labs	573.5	-10.8 (-1.9%)	Small Cap	5,041	3.7	3.1	157.3	7.5
Piramal Pharma	201.9	-0.1 (-0%)	Small Cap	4,390	5.2	8.4	39	3.8
Ajanta Pharma	2,541.2	-3.7 (-0.2%)	Small Cap	4,209	71.9	19	35.4	8.1
Gland Pharma	1,554.2	-23.6 (-1.5%)	Small Cap	4,167	68.1	24.8	23.2	2.8
Natco Pharma	780.8	-3.3 (-0.4%)	Small Cap	3,999	104.1	34.5	7.5	1.9
Granules India	471.2	-4.6 (-1%)	Small Cap	3,755	13.3	11.7	35.8	3.5
Emcure Pharma	926.4	0 (0%)	Small Cap	3,498	8.5	4.4	109.1	6.1
JB Chem & Pharma	1,518	13.3 (0.9%)	Small Cap	3,299	40.4	16.1	37.3	7.1
Sanofi India	5,587.9	32.6 (0.6%)	Small Cap	2,851	136.2	20.8	40.8	14.9

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Jun'13	Jun'14
Sales	69.48	154.46	197.54	294.84	370.44	491.96	657.34	730.19	337.50	31.50
Operating Expenses ⓘ	66.63	138.97	171.02	256.95	321.50	424.88	559.20	661.63	378.64	40.26
Manufacturing Costs	11.62	11.47	4.20	13	16.14	22.12	8.86	13.85	7.98	2.42
Material Costs	43.66	114.59	150.63	215.04	269.47	365.31	505.87	561.81	296.54	19.90
Employee Cost	5.42	5.81	7.28	10.80	15.10	15.53	17.68	19.99	10.13	4.81
Other Costs ⓘ	5.93	7.10	8.91	18.10	20.79	21.92	26.79	65.99	63.99	13.12
Operating Profit ⓘ	2.85	15.49	26.52	37.89	48.95	67.08	98.14	68.56	-41.14	-8.75
Operating Profit Margin (%)	4.1%	10.0%	13.4%	12.9%	13.2%	13.6%	14.9%	9.4%	-12.2%	-27.8%
Other Income ⓘ	2.89	2.63	1.10	1.97	2.74	2.68	3.17	1.04	0.19	0
Interest ⓘ	3.78	6.03	6.95	11.59	20.90	26.15	34.28	45.02	0.97	0.41
Depreciation ⓘ	1.25	1.67	1.56	1.63	2.57	3.05	3.65	5.11	6.40	4.97
Exceptional Items ⓘ	0	0	0	0	0	0	0	-15.03	-114.40	-125.45
Profit Before Tax ⓘ	0.71	10.42	19.11	26.63	28.21	40.55	63.38	4.44	-162.72	-139.58
Tax ⓘ	0	0.74	5.02	8.60	6.09	7.93	13.94	0.92	0	0
Profit After Tax	0.71	9.68	14.09	18.03	22.12	32.63	49.44	3.52	-162.72	-139.58
PAT Margin (%)	1.0%	6.3%	7.1%	6.1%	6.0%	6.6%	7.5%	0.5%	-48.2%	-443.0%
Adjusted EPS (₹)	0.8	10.1	6.6	8.5	10.4	15.3	23.2	1.4	-65.7	-56.3
Dividend Payout Ratio (%)	0%	0%	8%	12%	10%	10%	6%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Jun'13	Jun'14
Equity and Liabilities
Shareholders Fund	4.33	14.07	34.64	50.17	69.60	98.48	143.19	181.42	18.69	-120.91
Share Capital ⓘ	9.55	9.55	10.64	10.64	10.64	10.64	10.64	12.39	12.39	12.39
Reserves ⓘ	-5.22	4.52	24	39.52	58.96	87.84	132.55	169.03	6.29	-133.30
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	30.86	57.63	66.86	120.04	160.43	195.19	244.30	282.70	274.11	268.70
Long Term Debt	30.86	57.63	66.86	120.04	160.43	195.19	64.64	49.47	35.69	30.28
Short Term Debt	0	0	0	0	0	0	179.67	233.23	238.42	238.42
Trade Payables	10.83	17.93	18.17	24.33	26.92	34.75	39.89	34.55	25.77	23.64
Others Liabilities ⓘ	5.62	24.69	11.27	24	28.01	31.61	50.92	52.48	123.83	143.12
Total Liabilities ⓘ	51.64	114.32	130.94	218.53	284.95	360.04	478.31	551.15	442.39	314.55
Fixed Assets
Gross Block	32.79	44.92	40.04	45.25	72.24	84.49	101.73	120.33	120.26	120.61
Accumulated Depreciation	8.36	10.03	9.90	11.46	14.05	17.12	20.77	25.81	32.21	37.20
Net Fixed Assetsⓘ	24.43	34.89	30.14	33.79	58.19	67.37	80.97	94.52	88.05	83.42
CWIP ⓘ	0.87	0	0	7.21	5.25	9.83	7.42	7.42	0	0
Investmentsⓘ	0.06	0.10	0.10	0.04	0.04	0.04	10.72	10.72	10.72	10.72
Inventories	7.55	19	23.93	36.13	51.88	69.04	84.46	77.16	55.07	4.07
Trade Receivables	13.77	50.59	67.56	112.88	142.87	179.10	256.73	326.11	257.26	202.09
Cash Equivalents	1.33	1.78	1.91	2.25	4.30	5.96	2.64	1.69	0.18	0.85
Others Assetsⓘ	3.64	7.96	7.30	26.23	22.42	28.70	35.38	33.53	31.11	13.40
Total Assets ⓘ	51.64	114.32	130.94	218.53	284.95	360.04	478.31	551.15	442.39	314.55

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Jun'13	Jun'14
Cash Flow From Operating Activity ⓘ	3.68	-7.25	-2.37	-18.69	5.16	14.17	-5.46	1.52	-5.79	1.68
PBT ⓘ	0.71	10.42	19.11	26.63	28.21	40.55	63.38	4.44	-162.72	-139.58
Adjustment ⓘ	3.24	7.34	7.57	9.60	18.55	23.74	34.65	50.16	178.75	142.33
Changes in Working Capital ⓘ	-0.27	-24.15	-24.03	-46.32	-35.33	-43.14	-96.38	-52.61	-20.9	-0.88
Tax Paid ⓘ	-0.01	-0.86	-5.02	-8.60	-6.28	-6.98	-7.11	-0.47	-0.91	-0.19
Cash Flow From Investing Activity ⓘ	-0.25	-1.14	-0.78	-25	-24.51	-29.57	-24.65	-18.71	0.09	-0.36
Capex	-1.85	-1.11	-0.82	-12.52	-25.03	-16.83	-14.69	-18.72	0.06	-0.36
Net Investments	1.60	-0.04	0	0.07	0	0	-10.68	0	0	0
Others ⓘ	0	0	0.04	-12.54	0.52	-12.74	0.72	0.02	0.03	0
Cash Flow From Financing Activityⓘ	-3.43	8.60	3.18	44.03	21.41	17.06	26.79	16.24	4.19	-0.66
Net Proceeds from Shares ⓘ	1	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	-1.08	1.85	-3.33	34.22	0	0	5.51	-15.17	-0.03	-0.25
Interest Paid ⓘ	-3.59	-5.68	-6.05	-9.15	-16.50	-21.51	-31.87	-45.02	-0.97	-0.41
Dividend Paid ⓘ	0	0	0	0	-2.49	-3.72	-3.72	0	0	0
Others ⓘ	0.24	12.42	12.56	18.96	40.39	42.29	56.88	76.43	5.19	0
Net Cash Flow ⓘ	0	0.20	0.03	0.35	2.05	1.66	-3.32	-0.95	-1.51	0.66

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Jun'13	Jun'14
Ratios
ROE (%)	0	275.18	75.4	49.07	40.78	41.6	42.91	2.25	-172.23	N/A
ROCE (%)	15.45	30.66	30.02	29.36	25.25	25.66	27.97	11.24	-40.54	N/A
Asset Turnover Ratio	1.39	1.95	1.65	1.71	1.48	1.53	1.58	1.42	0.68	0.08
PAT to CFO Conversion(x)	5.18	-0.75	-0.17	-1.04	0.23	0.43	-0.11	0.43	N/A	N/A
Working Capital Days
Receivable Days	66	72	107	111	125	119	120	145	315	2,661
Inventory Days	52	30	39	37	43	45	42	40	71	343
Payable Days	107	43	41	28	24	21	22	24	37	453

Twilight Litaka Pharma Ltd Stock News

View All News

Twilight Litaka Pharma Ltd FAQs

What is the share price of Twilight Litaka Phar?

Company share prices are keep on changing according to the market conditions. The closing price of Twilight Litaka Phar on 01-Jan-1970 05:30 is ₹0.00.

What is the market cap of Twilight Litaka Phar?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 05:30 the market cap of Twilight Litaka Phar stood at ₹7.14.

What is the P/E ratio of Twilight Litaka Phar?

The latest P/E ratio of Twilight Litaka Phar as of 01-Jan-1970 05:30 is 0.00.

What is the P/B ratio of Twilight Litaka Phar?

The latest P/B ratio of Twilight Litaka Phar as of 01-Jan-1970 05:30 is -0.05.

What is the 52-week high and low of Twilight Litaka Phar?

The 52-week high of Twilight Litaka Phar is ₹2.88 and the 52-week low is ₹2.88.

What is the TTM revenue of Twilight Litaka Phar?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Twilight Litaka Phar is ₹12.49 ( Cr.) .

About Twilight Litaka Pharma Ltd

Twilight Litaka Pharma Ltd., formerly Li Taka Pharmaceuticals Ltd. was originally incorporated as Li Taka Pharmaceuticals Pvt. Ltd., on January 18,1974 under the Companies Act, 1956. Thereafter the said company was converted into a Public Limited Company and a fresh Certificate of Incorporation was obtained on December 9, 1985. The company came out with a Public Issue during the year 1986 for expansion, upgradation of its manufacturing facilities.

The company manufactures drugs and formulations in the form of tablets, capsules, ointment and liquids. The companyâ€™s products cover the following major therapeutic segments:

Analgesics - Anti Inflammatory
Anti-Asthmatic
Antibiotics
Anti-bacterials
Vitamins
Haematinics
Cardiovascular drugs

The company has well equipped, modern manufacturing testing and packaging facilities at all its plants viz. Pimpri, Vadgaon and Vasai. The Pimpri Plant has been approved by Dept. of Science and Technology, Government of India for its R & D facilities. The plants at Vadgaon and Pimpri have also been approved by the Pune University for laboratory use by its students pursuing the Doctorate Degrees.

The facilities at Pimpri and Vadgoan are as per the World Health Organisation guidelines and in conformity with Good Manufacturing Practices (GMP), enabling the company to register its products for exports in several countries all over the world.

The company also has a well established distribution network all over India (except in Delhi and Uttaranchal) with a customer base of over 1,00, 000 doctors for 120 formulations distributed through 1000 stockists. The domestic marketing personnel comprise of over 600 field force and is registered with several Central and State agencies to cater to the requirements of large hospitals, railways, ESIC, GMDs, Post and Telegraph Dept. city contractors, autonomous bodies and armed forces. The companyâ€™s business mix also includes an exclusive marketing arrangement with Cipla Ltd. for marketing of its brands across 10 states in the country.

Different divisions of the company:

TL Pharma has five divisions for Domestic Market

TLPL division:This division is also known as the Mother Division as it has products that form Centrum, Nucleus & Zenith divisions. This division holds the promise of very high growth rate in the turnover. This division is ably manned by 225 field personnel.
Nutra division :The company has entered the nutraceutical segment with an exclusive division focused on nutritional therapy. The divisionâ€™s foremost brand is â€œCALM CREAMâ€ â€“ a nutritional supplement for skin useful in treatment of psoriases and eczema. The focus of this division is on nutraceutical products that are used as adjuvant and support therapy segments like COQ CARE, ARTHRICARE, LBM CARE which will improve the quality of life of the patients.
Centrum Division:This division also focuses on servicing specialities like Gynecologists, Paediatricians, Physicians, Surgeons, Orthopaedic Surgeons, General Practitioners. This division has a range of life saving antibiotic injectables vital for use in surgeries & ICUs. Besides there is a range of products like Litacid, Temptal, Epixyl Expectorant & Litacold which provide excellent relief from day to day ailments. This division is ably manned by 400 field personnel.
Nucleus divisions :In these two divisions, the focus is on segments like the physicians, general practitioners, orthopaedics, surgeons and paediatricians. Some of their strong brands include Cefilite, Seratid,O1B, Paranac, Toxolite, Antif. The division is ably supported by over 500 field force, 125 Managers and marketed throughout the country
Zenith :This division focuses on servicing two specialities of medical practitioners viz. dermatologists and gynaecologists. The fraternity is presented with a range of products prescribed for their patients on a regular basis. This division is supported by 115 field personnel across India, in select towns.

Product range of the company includes:

Anti-Inflammatory / Analgesics / Anti-Pyretics
Antacids
Anthelmintics
Antibiotics
Anti - Emetics
Anti - Fungal
Anti - Protozoals Amoebicides
Calcium Supplements
Coagulants
Gynaecology
Expectorants / Cold Preparations / Mucolytics
Iron - Preparations Folic Acid
ORS
Vitamins
Tranquilizers
Topical Preparations
Tonics

Milestones:

In the year 1974 the company was incorporated as Li Taka Pharmaceuticals Pvt. Ltd
In the year 1988 Litaka Laboratories Pvt.amalgamated with the company under approved Scheme of Amalgamation.
In the year 1995 Pegasus Laboratories amalgamated with the company under approved Scheme of Amalgamation.
The Marketing Division of Borachem Industries was taken over by the company in the year 1997-98.
In the year 2000, Clover Pharmaceuticals Private. Amalgamated with the company under approved Scheme of Amalgamation
Care Unipac Pvt. merged with the company in pursuance of the order passed by the Honâ€™ble Bombay High Court on 28th April, 2006.
The Registrar of Companies, Pune issued a fresh certificate in the new name of the company i.e. Twilight Litaka Pharma Limited on 4th July, 2006
On 20th October, 2006 the Honâ€™ble Bombay High Court passed an order confirming the Scheme of Reduction of Share Capital of the company.